#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
CS
proLékaře.cz / Journals / Clinical Osteology / 2019 - 4

Bone disease in patients after organ transplantation

Czech version

Authors: Brunová Jana
Authors‘ workplace: Centrum diabetologie, endokrinologická ambulance IKEM, Praha
Published in: Clinical Osteology 2019; 24(4): 199-203
Category:

Overview

Organ transplantation is associated with the decrease in bone mass and increased incidence of low-energy fractures, whether in consequence of the previous illness or anti-rejection treatment and post-transplantation complications. All patients after organ transplant should be examined for possible bone involvement and appropriately treated. The basic measures to reduce the bone loss following transplantation primarily include, apart from the general rules for osteoporosis prevention, regulation of calcium phosphate metabolism, vitamin D insufficiency, secondary hyperparathyroidism, and reduction of the cumulative dose of glucocorticoids. Individualized antiresorptive treatment is suitable for patients at risk for osteoporotic fracture and/or decrease in bone density, despite the support treatment with calcium and vitamin D.

Keywords:

Organ transplantation – osteoporosis – treatment

Sources
  1. Anastasilakis AD, Tsouri E, Makras P et al. Bone disease following solid organ transplantation: A narrative review and recommendation for management from The European Calcified Tissue Society. Bone 2019; 127: 401–418. Dostupné z DOI: <http://dx.doi.org/10.1016/j.bone.2019.07.006>.
  2. Kulak CA, Borba VZ, Kulak J et al. Bone disease after transplantation: osteoporosis and fracture risk. Arq Bras Endocrinol Metabol 2014; 58(5): 484–492. Dostupné z DOI: <http://dx.doi.org/10.1590/0004–2730000003343>.
  3. Kulak CA, Borba VZ, Kulak J, jr, et al. Post-transplantation osteoporosis. Arq Bras Endocrinol Metabol 2010; 54(2): 143-149.Dostupné z DOI: <https://doi.org/10.1590/S0004-27302010000200009>.
  4. Alis G, Alis M, Erturk T et al. Evaluation of bone disease in kidney transplant recipients. Transplant Proc 2017; 49(3): 509–511. Dostupné z DOI: <http://dx.doi.org/10.1016/j.transproceed.2017.01.040>.
  5. Krol CG, Dekkers OM, Kroon HM et al. No association between BMD and prevalent vertebral fractures in liver transplant recipients at time of screening before transplantation. J Clin Endocrinol Metab 2014; 99(10): 3677–3685. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2014–1469>.
  6. Early C, Stuckey L, Tischer S. Osteoporosis in the adult solid organ transplant population: underlying mechanism and available treatment options. Osteoporosis Int 2016; 27(4): 1425–1440. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198–015–3367–8>.
  7. Kratochvilova S, Brunova J, Wohl P et al. Retrospective Analysis of Bone Metabolism in Patients on Waiting List for Simultaneous Pancreas-Kidney Transplantation. J Diabetes Res 2019; 2019: 5143021. Dostupné z DOI: <http://doi.org/10.1155/2019/5143021
  8. Nikkel LE, Hollenbeak CS, Fox EJ et al. Risk of fractures after renal transplantation in the United States. Transplantation 2009; 87(12): 1846–1851. Dostupné z DOI: <http://dx.doi.org/10.1097/TP.0b013e3181a6bbda>.
  9. Lan G-b, Xie X-b, Peng L-k et al. Current status of research on osteoporosis after solid organ transplantation: Pathogenesis and management. Biomed Res Int 2015; 2015:413169. Dostupné z DOI: <http://doi.org/10.1155/2015/413169>.
  10. Butin S, Griffoul I, Espitalier F et al. High incidence of vertebral osteoporotic fractures within the first year after liver transplantation. Clin Exp Rheumatol 2017; 35(6): 913–918.
  11. Kantalar-Zadeh K, Molnar MZ, Kovesdy CP et al. Management of mineral and bone disorders after kidney transplantation. Curr Opin Nephrol Hypertens 2012; 21(4): 389–403. Dostupné z DOI: <http://dx.doi.org/10.1097/MNH.0b013e3283546ee0>.
  12. Gosmanova EO, Gosmanov AR. Osteoporosis in patients with diabetes after kidney transplantation. Rev Endocr Metab Disord 2017; 18(1): 97–106. Dostupné z DOI: <http://dx.doi.org/10.1007/s11154–016–9397–5>.
  13. Corey RL, Whitaker MD, Crowell MD et al. Vitamin D deficiency, parathyroid hormone level, and bone disease among patients with end- stage liver disease and normal serum creatinine awaiting liver transplantation. Clin Transpl 2014; 28(5): 579–584. Dostupné z DOI: <http://dx.doi.org/10.1111/ctr.12351>.
  14. Gregorini M, Sileno G, Pattonieri EF et al. Understanding bone damage after kidney transplantation: A retrospective monocentric cross sectional analysis. Transpl Proc 2017; 49(4): 650–657. Dostupné z DOI: <http://dx.doi.org/10.1016/j.transproceed.2017.02.023>.
  15. Damasiewitz MJ, Ebeling PR. Management of mineral and bone disorders in renal transplant recipients. Nephrology (Carlton) 2017; 22(Suppl 2): 65–69. Dostupné z DOI: <http://dx.doi.org/10.1111/nep.13028>.
  16. Ebeling PR. Approach to the patient with transplantation-related bone loss. J Clin Endocrinol Metab 2009; 94(5): 1483–1490. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2009–0205>.
  17. Rocha A, Martins L, Malheiro J et al. Changes in bone mineral density following long-term simultaneous pankreas-kidney transplantation. J Bone Miner Metab 2016; 34(2): 209–215. Dostupné z DOI: <http://dx.doi.org/10.1007/s00774–015–0657–3>.
  18. Krol CG, Dekkers OM, Kroon HM et al. Longitudinal changes in BMD and fracture risk in orthotopic liver transplant recipients not using bone-modifying treatment. J Bone Miner Res 2014; 29(8): 1763–1769. Dostupné z DOI: <http://dx.doi.org/10.1002/jbmr.2214>.
  19. Hardy RS, Zhou H, Seibel HJ et al. Glucocorticoids and bone consequences of endogenous and exogenous excess and replacement therapy. Endokr Rev 2018; 39(5): 519–548. Dostupné z DOI: <http://dx.doi.org/10.1210/er.2018–00097>.
  20. Perrin P, Caillard D, Javier RM et al. Persistent hyperparathyroidism is a major risk factor for fractures in the 5 years after kidney transplantation. Am J Transpl 2013; 13(10): 2653–2663. Dostupné z DOI: <http://dx.doi.org/10.1111/ajt.12425>.
  21. Naylor KL, Lix LM, Hans D et al. Trabecular bone score in kidney transplant recipients. Osteoporos Int 2016; 27(3): 1115–1121. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198–015–3424–3>.
  22. Chandran M, Hao Y, Kwee AK et al. Addressing bone quality and bone density after renal transplantation: A prospective evaluation of the evolution of trabecular bone score and bone mineral density over the first 5 years following renal transplantation in Asian patients. Clin Transplant 2019; 33(10): e13671. Dostupné z DOI: <http://doi.org/10.1111/ctr.13671>.
  23. Brunova J, Kratochvilova S, Stepankova J. Osteoporosis therapy with denosumab in organ transplant recipients. Front Endocrinol (Lausanne) 2018; 9: 162. Dostupné z DOI: <http://dx.doi.org/10.3389/fendo.2018.00162>.
  24. Stein EM, Ortiz D,Ji Z et al. Prevention of fractures after solid organ transplantation: a meta-analysis. J Clin Endocrinol Metab 2011; 96(11): 3457–3465. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2011–1448>.
  25. Kan SL, Ning GZ, Chen LX et al. Efficacy and safety of bisphosphonates for low bone mineral density after kidney transplantation: a meta-analysis. Medicine (Baltimore) 2016; 95(5): e2679. Dostupné z DOI: <http://dx.doi.org/10.1097/MD.0000000000002679>.
  26. Khan A, Morrison A, Cheung A et al. Osteonecrosis of the jaw (ONJ): diagnosis and management in 2015. Osteoporosis Int 2016; 27(3): 853–859. Dostupné z DOI: <http://doi.org/10.1007/s00198–015–3335–3>.
  27. Kasturi KS, Chennareddygari S, Mummadi RR. Effect of bisfosfonates on bone mineral density on bone density in liver transplant patients: a meta-analysis and systemic review on randomized controlled trials. Transpl Int 2010; 23(2): 200–207. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1432–2277.2009.00976.x>.
  28. Cejka D, Benesch T, Krestan C et al. Effect of teriparatide on early bone loss after kidney transplantation. Am J Transpl 2008; 8(9): 1864–1870. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1600–6143.2008.02327.x>.
  29. Papapoulos S, Lippuner K, Roux C et al. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM extension study. Osteoporos Int 2015; 26(12): 2773–2783. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198–015–3234–7>.
  30. Bonani M, Meyer U, Frey D et al. Effect of denosumab on peripheral compartment bone density, microarchitecture and extimated bone strength in de novo kidney transplant recipients. Kidney Blood Press Res 2016; 41(5): 614–622. Dostupné z DOI: <http://dx.doi.org/10.1159/000447930>.
  31. Bonani M, Frey D, Graf N et al. Effect of denosumab on trabecular bone score in de novo kidney transplant recipients. Nephrol Dial Transplant 2019; 34(10): 1773–1780. Dostupné z DOI: <http://dx.doi.org/10.1093/ndt/gfy411>.
Labels
Clinical biochemistry Paediatric gynaecology Paediatric radiology Paediatric rheumatology Endocrinology Gynaecology and obstetrics Internal medicine Orthopaedics General practitioner for adults Radiodiagnostics Rehabilitation Rheumatology Traumatology Osteology
Background theses for the formulation of guidelines on diagnosis and therapy metabolic bone disease as a part of CKD-MBD, with specific focus on low mineral bone content in DXA examination
Densitometry in patients with chronic kidney disease
Association between bone and vascular calcification: evidence from clinical studies
Calciphylaxis as a multidisciplinary problem: important information (not only) for clinical osteologists and case reports
ODPORÚČANIE SOMOK DLHODOBÁ LIEČBA OSTEOPORÓZY DENOSUMABOM
První biosimilár k léčbě osteoporózy v EU schválen!
Article was published in

Clinical Osteology

Issue 4
2019 Issue 4
Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#